Matthew Fuchter

Matthew John Fuchter FRSC is a British chemist who is a Professor of Chemistry at Imperial College London.[1] His research focuses on the development and application of novel functional molecular systems to a broad range of areas; from materials to medicine. He is a Fellow of the Royal Society of Chemistry in 2014.[2] In 2020 he was a finalist for the Blavatnik Awards for Young Scientists.

Matthew Fuchter

FRSC
Born
Matthew John Fuchter

England, United Kingdom
NationalityBritish
Alma materUniversity of Bristol
Imperial College London
AwardsHarrison-Meldola Memorial Prize (2014)
Scientific career
InstitutionsUniversity of Melbourne
Imperial College London
University College London
ThesisSynthetic studies on porphyrazines : biological applications and new preparative methods (2006)
Doctoral advisorAnthony Barrett
Websitewww.imperial.ac.uk/people/m.fuchter

Early life and education

Fuchter earned a master's degree (MSci) in chemistry at the University of Bristol, where he was awarded the Richard Dixon prize.[3] It was during his undergraduate degree that he first became interested in organic synthesis.[4] As a graduate student he moved to Imperial College London, where he worked with Anthony Barrett on the synthesis and applications of porphyrazines, including as therapeutic agents.[5][6] During his doctoral studies Barrett and Fuchter collaborated with Brian M. Hoffman at Northwestern University.[2]

Research and career

After completing his PhD, Fuchter moved to Australia, for postdoctoral research at CSIRO and the University of Melbourne, where he worked with Andrew Bruce Holmes.[2][7] In 2007 Fuchter returned to the United Kingdom, where he began his independent academic career at the School of Pharmacy, University of London (now UCL School of Pharmacy).[2] Less than one year later he was appointed a Lecturer at Imperial College London, where he was promoted to Reader (Associate Professor) in 2015 and Professor in 2019.[2][8]

Fuchter is interested in how considerations of chirality can be applied to the development of novel approaches in chiral optoelectronic materials and devices.[2] In particular, he focusses on the introduction of chiral-optical (so-called chiroptical) properties into optoelectronic materials.[2] Amongst these materials, Fuchter has extensively evaluated the use of chiral small molecule additives (helicenes[7]) to induce chiroptical properties into light emitting polymers for the realisation of chiral (circularly polarised, CP) OLEDs.[2][7] He has also investigated the application of such materials in circularly polarised photodetectors, which are devices that are capable of detecting circularly polarised light.[2] As well as using chiral functional materials for light emission and detection, Fuchter has investigated the charge transport properties of enantiopure and racemic chiral functional materials.

Fuchter has also developed novel molecular photoswitches – molecules that can be cleanly and reversibly interconverted between two states using light – with a focus on heteroaromatic versions of azobenzene. The arylazopyrazole switches developed by Fuchter out perform the ubiquitous azobenzene switches, demonstrating complete photoswitching in both directions and thermal half-lives of the Z isomer of up to 46 years. Fuchter continues to apply these switches to a range of photoaddressable applications from photopharmacology to energy storage.

Alongside his work on functional material discovery, Fuchter works in medicinal chemistry and develops small molecule ligands that can either inhibit or stimulate the activity of disease relevant proteins.[2][9] While he has worked on many drug targets, he has specialised in proteins involved in the transcriptional and epigenetic processes of disease. A particular interest has been the development of inhibitors for the histone-lysine methyltransferase enzymes in the Plasmodium parasite that causes human malaria.[10]

In 2018 one of the cancer drugs developed by Fuchter, together with Anthony Barrett, Simak Ali and Charles Coombes entered a phase 1 clinical trial, and as of 2020, it is in phase 2.[7][11] The drug, which was designed using computational chemistry, inhibits the cyclin-dependent kinase 7 (CDK7), a transcriptional regulatory protein that also regulates the cell cycle. Certain cancers rely on CDK7, so inhibition of this enzyme has potential to have a significant impact on cancer pathogenesis.[11]

Academic service

Fuchter serves on the editorial board of MedChemComm.[12] He is an elected council member of the Royal Society of Chemistry organic division.[13] Fuchter is co-Director of the Imperial College London Centre for Drug Discovery Science.[14]

Awards and honours

Selected publications
  • Malmquist, N. A.; Moss, T. A.; Mecheri, S.; Scherf, A.; Fuchter, M. J. (2012). "Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum". Proceedings of the National Academy of Sciences. 109 (41): 16708–16713. doi:10.1073/pnas.1205414109. ISSN 0027-8424. PMC 3478629. PMID 23011794.
  • Cherblanc, Fanny L; Chapman, Kathryn L; Brown, Robert; Fuchter, Matthew J (2013). "Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases". Nature Chemical Biology. 9 (3): 136–137. doi:10.1038/nchembio.1187. ISSN 1552-4450. PMID 23416387.
  • Dembélé, Laurent; Franetich, Jean-François; Lorthiois, Audrey; Gego, Audrey; Zeeman, Anne-Marie; Kocken, Clemens H. M.; Le Grand, Roger; Dereuddre-Bosquet, Nathalie; van Gemert, Geert-Jan; Sauerwein, Robert; Vaillant, Jean-Christophe (2014). "Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures". Nature Medicine. 20 (3): 307–312. doi:10.1038/nm.3461. ISSN 1546-170X. PMID 24509527.
  • Gerkman, Mihael A.; Gibson, Rosina S. L.; Calbo, Joaquín; Shi, Yuran; Fuchter, Matthew J.; Han, Grace G. D. (2020). "Arylazopyrazoles for Long-Term Thermal Energy Storage and Optically Triggered Heat Release below 0 °C". Journal of the American Chemical Society. 142 (19): 8688–8695. doi:10.1021/jacs.0c00374. ISSN 0002-7863.
  • Yang, Ying; da Costa, Rosenildo Correa; Fuchter, Matthew J.; Campbell, Alasdair J. (2013). "Circularly polarized light detection by a chiral organic semiconductor transistor". Nature Photonics. 7 (8): 634–638. doi:10.1038/nphoton.2013.176. ISSN 1749-4893.
  • Yang, Ying; Costa, Rosenildo Correa da; Smilgies, Detlef-M.; Campbell, Alasdair J.; Fuchter, Matthew J. (2013). "Induction of Circularly Polarized Electroluminescence from an Achiral Light-Emitting Polymer via a Chiral Small-Molecule Dopant". Advanced Materials. 25 (18): 2624–2628. doi:10.1002/adma.201204961. ISSN 1521-4095. PMC 3659407. PMID 23554220.
  • Brandt, Jochen R.; Wang, Xuhua; Yang, Ying; Campbell, Alasdair J.; Fuchter, Matthew J. (2016). "Circularly Polarized Phosphorescent Electroluminescence with a High Dissymmetry Factor from PHOLEDs Based on a Platinahelicene". Journal of the American Chemical Society. 138 (31): 9743–9746. doi:10.1021/jacs.6b02463. ISSN 0002-7863.
gollark: The interior picture does make it look bigger.
gollark: Is it meant to be (hemi)*spherical* or something?
gollark: Sometimes people are just bad. Like when they go "OH NO AN ERROR I will now proceed to wallow in helplessness and ignore anything it says".
gollark: Programming is useful and important. Though I do wish people had more BASIC COMPUTER USAGE KNOWLEDGE ÆÆÆÆÆÆÆÆÆÆÆ.
gollark: > someone keeps tapping into my PC with donglesWhat do you mean?

References
  1. Matthew Fuchter publications from Europe PubMed Central
  2. "Interview with Matthew J. Fuchter - SYNFORM - Thieme Chemistry". Thieme. Retrieved 2020-06-24.
  3. "Prof. A.G.M. Barrett, FRS". ic.ac.uk. Retrieved 2020-06-24.
  4. Zanda, Matteo (2015-10-20). "SYNFORM ISSUE 2015/11". Synthesis. 47 (21): A150–A166. doi:10.1055/s-0035-1560202. ISSN 0039-7881.
  5. Fuchter, Matthew John (2006). Synthetic studies on porphyrazines: biological applications and new preparative methods. london.ac.uk (PhD thesis). University of London. OCLC 500152201. EThOS 423302.
  6. "Chemistry Tree - Anthony GM Barrett". academictree.org. Retrieved 2020-06-24.
  7. Newton, Jennifer (2020-04-29). "Introducing chirality to give organic electronics a twist". chemistryworld.com. Chemistry World. Retrieved 2020-06-24.
  8. "The central science: using molecules to develop materials and medicine". Imperial College London. Retrieved 2020-06-24.
  9. "a collaboration with Dr Holger Auner and Prof Matthew Fuchter, Imperial College London". Apollo Therapeutics. Retrieved 2020-06-24.
  10. Fuchter, Matt. "Novel Antimalarial Drugs Through Epigenetics: Full Interview with Dr Matt Fuchter". Pharma IQ. Retrieved 2020-06-24.
  11. "Imperial-developed cancer drug enters phase I clinical trial – NIHR Imperial Biomedical Research Centre". nihr.ac.uk. Retrieved 2020-06-24.
  12. "Introducing MedChemComm Associate Editor Dr Matthew Fuchter – RSC Medicinal Chemistry Blog". Retrieved 2020-06-24.
  13. "Organic Division Council Members". rsc.org. Retrieved 2020-06-24.
  14. "Associated Groups". LMS London Institute of Medical Sciences. Retrieved 2020-06-24.
  15. "Harrison-Meldola Memorial Prize Winner 2014". rsc.org. Retrieved 2020-06-24.
  16. "Five Imperial academics win Royal Society of Chemistry awards". Science|Business. Retrieved 2020-06-24.
  17. "Matt Fuchter wins Tetrahedron Young Investigator Award". imperial.ac.uk. Imperial College London. Retrieved 2020-06-24.
  18. "Matthew Fuchter - EPSRC website". epsrc.ukri.org. Retrieved 2020-06-24.
  19. "Matthew Fuchter | Blavatnik Awards for Young Scientists". blavatnikawards.org. Retrieved 2020-06-24.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.